Spots Global Cancer Trial Database for folfiri
Every month we try and update this database with for folfiri cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | NCT02563002 | Colorectal Carc... | mFOLFOX6 FOLFIRI pembrolizumab bevacizumab cetuximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment | NCT00839111 | Colorectal Neop... | sorafenib FOLFIRI | 18 Years - 75 Years | Fudan University | |
| 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma | NCT01277406 | Advanced Colore... | 4SC-201(Resmino... FOLFIRI | 18 Years - | 4SC AG | |
| FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | NCT01133990 | Colorectal Canc... | FOLFIRI E7820 Bevacizumab | 18 Years - | Eisai Inc. | |
| A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI | NCT04247256 | Metastatic Colo... | FOLFIRI Protoco... SCO-101 | 18 Years - | Scandion Oncology A/S | |
| FOLFIRI and Sunitinib in Metastatic Colorectal Cancer | NCT00806663 | Metastatic Colo... Liver Metastase... | sunitinib added... | 18 Years - 80 Years | Central European Society for Anticancer Drug Research | |
| Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination With 5-Fluorouracil (5FU) /or in FOLFIRI Regimen | NCT04680104 | Gastrointestina... CALCIUM LEVOFOL... SODIUM LEVOFOLI... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | ||
| Metastatic Gastric Cancer FFCD 03-07 | NCT00374036 | Stomach Cancer Neoplasm Metast... | ECC FOLFIRI | 18 Years - | University Hospital, Toulouse | |
| Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment | NCT02624726 | Metastatic Colo... | 5 Fluorouracil Leucovorin Irinotecan Aflibercept | 18 Years - | Hellenic Oncology Research Group | |
| Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | NCT01347645 | Colon Cancer Rectal Cancer | FOLFIRI E7820 | 18 Years - | Eisai Inc. | |
| Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer | NCT00719199 | Colorectal Canc... | IMO-2055 Cetuximab FOLFIRI | 18 Years - | EMD Serono | |
| MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab | NCT04554836 | Adenocarcinoma ... Adenocarcinoma ... | Cetuximab FOLFIRI | 18 Years - 99 Years | TheraOp | |
| FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma | NCT03528876 | Metastatic Gast... | FOLFOX and FOLF... | 18 Years - | University of Saskatchewan | |
| Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer | NCT00286130 | Metastatic Colo... | Cetuximab, Oxal... FOLFOX 6 FOLFIRI | 18 Years - | Central European Cooperative Oncology Group | |
| A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | NCT02033551 | Breast Cancer Ovarian Cancer Colon Cancer Lung Cancer Gastric Cancer Solid Tumors | Veliparib Carboplatin Paclitaxel FOLFIRI | 18 Years - 99 Years | AbbVie | |
| Erbitux MEtastatic Colorectal Cancer Strategy Study | NCT02484833 | Antineoplastic ... | Cetuximab FOLFIRI | 18 Years - | Catholic University of the Sacred Heart | |
| Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | NCT03117972 | Metastatic Colo... | FOLFOXIRI FOLFOX FOLFIRI Bevacizumab LV5FU2 Capecitabine | 18 Years - 76 Years | Centre Hospitalier Universitaire de Besancon | |
| mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy | NCT05362617 | Metastatic Colo... | FOLFIRI | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers | NCT05087992 | Gastrointestina... | BI 905711 FOLFIRI Bevacizumab | 18 Years - | Boehringer Ingelheim | |
| Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC | NCT04952753 | Metastatic Colo... | NIS793 Bevacizumab Modified FOLFOX... FOLFIRI Tislelizumab | 18 Years - | Novartis | |
| Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI | NCT01605344 | Advanced Adenoc... | FOLFIRI. Atorvastatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer | NCT03732235 | Liver Metastasi... | TACE+ systemic ... FOLFIRI+Bevaciz... TACE | 18 Years - | International Group of Endovascular Oncology | |
| Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI | NCT01020630 | Adenocarcinoma | Sunitinib Placebo | 18 Years - | Johannes Gutenberg University Mainz | |
| A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab | NCT03368859 | Cancer | Leucovorin Fluorouracil - ... Bevacizumab Fluorouracil - ... ABT-165 Irinotecan | 18 Years - | AbbVie | |
| Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | NCT02568046 | Metastatic Colo... | Sym004 FOLFIRI | 18 Years - | Symphogen A/S | |
| Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy | NCT03081143 | Advanced Gastri... | FOLFIRI Ramucirumab Paclitaxel | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of ABT-165 in Subjects With Solid Tumors | NCT01946074 | Advanced Solid ... | paclitaxel FOLFIRI ABT-165 ABBV-181 | 18 Years - 99 Years | AbbVie | |
| FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | NCT01133990 | Colorectal Canc... | FOLFIRI E7820 Bevacizumab | 18 Years - | Eisai Inc. | |
| Phase 2 Study of DKN-01 in Colorectal Cancer | NCT05480306 | Colorectal Canc... Colorectal Aden... Colo-rectal Can... Colorectal Canc... | DKN-01 FOLFIRI Bevacizumab FOLFOX | 18 Years - | Leap Therapeutics, Inc. | |
| Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | NCT03806309 | Pancreatic Duct... Locally Advance... Metastatic Canc... | FOLFIRI OSE2101 | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy | NCT03081143 | Advanced Gastri... | FOLFIRI Ramucirumab Paclitaxel | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen | NCT00561470 | Colorectal Neop... Neoplasm Metast... | Placebo Aflibercept (zi... FOLFIRI (Irinot... FOLFIRI (Irinot... | 18 Years - | Sanofi | |
| A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer | NCT05684211 | Colorectal Canc... | Ametumumab Anti-PD-1 monoc... Cetuximab FOLFIRI | 18 Years - 85 Years | Shanghai Celfuture Biotech Co., Ltd. | |
| Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer | NCT02849106 | Colorectal Canc... | biopsy to obtai... | 18 Years - | Institut Curie | |
| Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin | NCT00976768 | Advanced Gastri... | oxaliplatin, 5-... | 18 Years - | Asan Medical Center | |
| wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients | NCT01736904 | Colorectal Canc... | wXELIRI regimen FOLFIRI regimen | 18 Years - 70 Years | Fudan University | |
| Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer | NCT02820857 | Neuroendocrine ... | Folfiri-bevaciz... Folfiri | 18 Years - | Hospices Civils de Lyon | |
| Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI | NCT01605344 | Advanced Adenoc... | FOLFIRI. Atorvastatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients | NCT00354978 | Colorectal Canc... | 5-Fluorouracil Bevacizumab Leucovorin Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 2 Study of DKN-01 in Colorectal Cancer | NCT05480306 | Colorectal Canc... Colorectal Aden... Colo-rectal Can... Colorectal Canc... | DKN-01 FOLFIRI Bevacizumab FOLFOX | 18 Years - | Leap Therapeutics, Inc. | |
| A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | NCT05004350 | BRAF V600E Metastatic Colo... | Encorafenib Cetuximab FOLFIRI | 18 Years - | Pierre Fabre Medicament | |
| A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies | NCT03082209 | Advanced Solid ... Cancer Hematologic Mal... | ABBV-621 Venetoclax Bevacizumab FOLFIRI | 18 Years - | AbbVie | |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | NCT03597581 | Gastrointestina... Gastrointestina... Colorectal Canc... Colorectal Neop... Colorectal Carc... Gastric Cancer Gastric Neoplas... KRAS Mutation-R... CRC Colorectal Canc... | ompenaclid FOLFIRI Bevacizumab FOLFOX regimen | 18 Years - | Inspirna, Inc. | |
| A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma | NCT00752570 | Cancer Carcinoma Colon Cancer Colorectal Canc... Gastrointestina... Metastases Metastatic Canc... Metastatic Colo... Oncology Rectal Cancer | AMG 386 AMG 386 Placebo FOLFIRI | 18 Years - | Amgen | |
| Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination With 5-Fluorouracil (5FU) /or in FOLFIRI Regimen | NCT04680104 | Gastrointestina... CALCIUM LEVOFOL... SODIUM LEVOFOLI... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | ||
| Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer | NCT04446793 | Metastatic Colo... KRAS Gene Mutat... | Onvansertib Bevacizumab FOLFIRI | 18 Years - | Cardiff Oncology | |
| Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | NCT02305758 | Untreated Metas... | Veliparib Placebo Modified FOLFIR... FOLFIRI Bevacizumab Fluorouracil in... | 18 Years - 99 Years | AbbVie | |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | NCT05593328 | Colorectal Canc... Metastatic Colo... | Onvansertib FOLFIRI Bevacizumab | 18 Years - | Cardiff Oncology | |
| A Study in Second Line Metastatic Colorectal Cancer | NCT01183780 | Colorectal Canc... | Ramucirumab Placebo Irinotecan Folinic Acid 5-Fluorouracil | 18 Years - | Eli Lilly and Company | |
| Molecularly Tailored Therapy for Pancreas Cancer | NCT01888978 | Pancreatic Canc... | Gem-OX Gem-5FU Gem-Tax Modified FOLFOX... Ox-Tax FOLFIRI Tax-Iri | 18 Years - | Georgetown University | |
| FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma | NCT02023593 | Advanced Esopha... | FOLFIRI | 18 Years - 75 Years | Sun Yat-sen University | |
| Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination With 5-Fluorouracil (5FU) /or in FOLFIRI Regimen | NCT04680104 | Gastrointestina... CALCIUM LEVOFOL... SODIUM LEVOFOLI... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | ||
| mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line | NCT03464968 | Biliary Cancer ... | Oxaliplatin,5FU... irinotecan,5FU,... | 20 Years - | Seoul National University Bundang Hospital | |
| QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma | NCT00813605 | Metastatic Colo... | FOLFIRI AMG 655 Placebo AMG 479 | 18 Years - | NantCell, Inc. | |
| Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma | NCT04270929 | Pancreatic Aden... | FOLFIRI FOLFIRINOX TriSalus Infusi... | 18 Years - 80 Years | Roger Williams Medical Center | |
| A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 | NCT02482441 | Advanced Relaps... Refractory Soli... | OMP-131R10 FOLFIRI | 18 Years - | Mereo BioPharma | |
| A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | NCT03454620 | Metastatic Colo... Solid Tumor | irinotecan FOLFIRI | 19 Years - | GC Biopharma Corp | |
| Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy | NCT00332163 | Metastatic Colo... Skin Rash Skin Toxicities Colon Cancer Colorectal Canc... | Panitumumab Irinotecan FOLFIRI Pre-emptive Ski... Reactive Skin T... | 18 Years - 90 Years | Amgen | |
| SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | NCT00418938 | Cancer Colon Cancer Colorectal Canc... Metastatic Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | Amgen | |
| Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments | NCT01124630 | Metastatic Colo... | CS-1008 FOLFIRI | 18 Years - | Daiichi Sankyo | |
| Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. | NCT01068132 | Colorectal Canc... | Cetuximab FOLFIRI | 18 Years - 80 Years | Regione Lombardia | |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | NCT06252649 | Metastatic Colo... | FOLFIRI Regimen Sotorasib Panitumumab Bevacizumab-aww... | 18 Years - | Amgen | |
| MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab | NCT04554836 | Adenocarcinoma ... Adenocarcinoma ... | Cetuximab FOLFIRI | 18 Years - 99 Years | TheraOp | |
| A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer | NCT01326000 | Colorectal Canc... | FOLFIRI RO5083945 cetuximab | 18 Years - | Hoffmann-La Roche | |
| Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer | NCT02045030 | Metastatic Colo... | aflibercept + F... | 18 Years - | CR-CSSS Champlain-Charles-Le Moyne | |
| A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | NCT00636610 | Metastatic Colo... | Vismodegib 150 ... Placebo to vism... Bevacizumab Modified FOLFOX FOLFIRI | 18 Years - | Genentech, Inc. | |
| Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer | NCT02849106 | Colorectal Canc... | biopsy to obtai... | 18 Years - | Institut Curie | |
| Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone | NCT00339183 | Metastatic Colo... | Panitumumab FOLFIRI | 18 Years - | Amgen | |
| Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI | NCT00934882 | Colorectal Neop... | Regorafenib (BA... | 18 Years - | Bayer | |
| Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination With 5-Fluorouracil (5FU) /or in FOLFIRI Regimen | NCT04680104 | Gastrointestina... CALCIUM LEVOFOL... SODIUM LEVOFOLI... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | ||
| Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer | NCT00101894 | Rectal Cancer Colon Cancer | FOLFOX-4 AMG 706 Panitumumab (Pa... FOLFIRI | 18 Years - | Amgen | |
| Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques | NCT01704703 | Stage IV Colore... | panitumumab FOLFIRI | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | NCT05593328 | Colorectal Canc... Metastatic Colo... | Onvansertib FOLFIRI Bevacizumab | 18 Years - | Cardiff Oncology | |
| A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma | NCT00752570 | Cancer Carcinoma Colon Cancer Colorectal Canc... Gastrointestina... Metastases Metastatic Canc... Metastatic Colo... Oncology Rectal Cancer | AMG 386 AMG 386 Placebo FOLFIRI | 18 Years - | Amgen | |
| FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer | NCT01219920 | Metastatic Colo... | FOLFIRI FOLFOXIRI | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | NCT03692429 | Unresectable Me... | CYAD-101 FOLFOX FOLFIRI | 18 Years - | Celyad Oncology SA | |
| Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | NCT02138617 | Colon Cancer | 5-Fluorouracil Leucovorin Irinotecan Bevacizumab | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | NCT05733689 | Gastroesophagea... | ctDNA Blood Tes... FLOT FOLFOX FOLFIRI FOLFIRINOX PACLITAXEL with... DOCETAXEL and I... NIVOLUMAB (alon... PEMBROLIZUMAB (... | 18 Years - | University of California, Irvine | |
| 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma | NCT01277406 | Advanced Colore... | 4SC-201(Resmino... FOLFIRI | 18 Years - | 4SC AG | |
| Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | NCT02138617 | Colon Cancer | 5-Fluorouracil Leucovorin Irinotecan Bevacizumab | 18 Years - | UNC Lineberger Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
